Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City

Daniel Stadlbauer, Jessica Tan, Kaijun Jiang, Matthew M. Hernandez, Shelcie Fabre, Fatima Amanat, Catherine Teo, Guha Asthagiri Arunkumar, Meagan McMahon, Christina Capuano, Kathryn Twyman, Jeffrey Jhang, Michael D. Nowak, Viviana Simon (), Emilia Mia Sordillo (), Harm Bakel () and Florian Krammer ()
Additional contact information
Daniel Stadlbauer: Icahn School of Medicine at Mount Sinai
Jessica Tan: Icahn School of Medicine at Mount Sinai
Kaijun Jiang: Icahn School of Medicine at Mount Sinai
Matthew M. Hernandez: Icahn School of Medicine at Mount Sinai
Shelcie Fabre: Icahn School of Medicine at Mount Sinai
Fatima Amanat: Icahn School of Medicine at Mount Sinai
Catherine Teo: Icahn School of Medicine at Mount Sinai
Guha Asthagiri Arunkumar: Icahn School of Medicine at Mount Sinai
Meagan McMahon: Icahn School of Medicine at Mount Sinai
Christina Capuano: Icahn School of Medicine at Mount Sinai
Kathryn Twyman: Mount Sinai Health System
Jeffrey Jhang: Icahn School of Medicine at Mount Sinai
Michael D. Nowak: Icahn School of Medicine at Mount Sinai
Viviana Simon: Icahn School of Medicine at Mount Sinai
Emilia Mia Sordillo: Icahn School of Medicine at Mount Sinai
Harm Bakel: Icahn School of Medicine at Mount Sinai
Florian Krammer: Icahn School of Medicine at Mount Sinai

Nature, 2021, vol. 590, issue 7844, 146-150

Abstract: Abstract In late 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first detected in China and has since caused a pandemic of coronavirus disease 2019 (COVID-19). The first case of COVID-19 in New York City was officially confirmed on 1 March 2020 followed by a severe local epidemic1. Here, to understand seroprevalence dynamics, we conduct a retrospective, repeated cross-sectional analysis of anti-SARS-CoV-2 spike antibodies in weekly intervals from the beginning of February to July 2020 using more than 10,000 plasma samples from patients at Mount Sinai Hospital in New York City. We describe the dynamics of seroprevalence in an ‘urgent care’ group, which is enriched in cases of COVID-19 during the epidemic, and a ‘routine care’ group, which more closely represents the general population. Seroprevalence increased at different rates in both groups; seropositive samples were found as early as mid-February, and levelled out at slightly above 20% in both groups after the epidemic wave subsided by the end of May. From May to July, seroprevalence remained stable, suggesting lasting antibody levels in the population. Our data suggest that SARS-CoV-2 was introduced in New York City earlier than previously documented and describe the dynamics of seroconversion over the full course of the first wave of the pandemic in a major metropolitan area.

Date: 2021
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/s41586-020-2912-6 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:590:y:2021:i:7844:d:10.1038_s41586-020-2912-6

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/s41586-020-2912-6

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().